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Isolated Spinal Cord Neurosarcoidosis Diagnosed by Cord Biopsy 
and Thalidomide Trial
We report a case of 54-yr-old woman who presented with 4-extremities weakness and 
sensory changes, followed by cervical spinal cord lesion in magnetic resonance imaging. 
Based on the suspicion of spinal tumor, spinal cord biopsy was performed, and the 
histology revealed multinucleated giant cells, lymphocytes and aggregated histiocytes 
within granulomatous inflammation, consistent with non-caseating granuloma seen in 
sarcoidosis. The patient was treated with corticosteroid, immunosuppressant and 
thalidomide for years. Our case indicates that diagnosis of spinal cord sarcoidosis is 
challenging and may require histological examination, and high-dose corticosteroid and 
immunosuppressant will be a good choice in the treatment of spinal cord sarcoidosis, and 
the thalidomide has to be debated in the spinal cord sarcoidosis.
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Sarcoidosis is a systemic granulomatous disease of unknown 
origin, characterized by the presence of noncaseating granulo-
ma in affected organs (1). Lesions are commonly seen in the 
lungs, lymphatic system, eyes, skin, liver, spleen, salivary glands, 
heart, nervous system, muscles, and bones (1, 2). Although neu-
rosarcoidosis is a rare manifestation of sarcoidosis, the clinical 
symptoms can be devastating and occasionally life-threatening. 
The diagnosis of neurosarcoidosis can be challenging because 
the disease can present with a lot of symptoms and diverse radio-
logic findings (1-5). Among them, spinal sarcoidosis is a very rare 
entity, occurring in < 1%, and can be manifested as intramedul-
lary, intradural extramedullary, intraspinal epidural spaces and 
in vertebral bodies (6). In Korea, only a few cases of neurosar-
coidosis involving brain, spinal nerve root, peripheral nerve and 
spinal dura, have been reported with or without histological con-
firmation in the literature. However spinal cord sarcoidosis has 
not been documented in Korea. In general, patients with spinal 
sarcoidosis are considered to be at high risk for severe neurolog-
ical sequelae (7). The information available about spinal sarcoid-
osis management and diagnosis comes from a few case reports, 
small series and expert opinions (8-10). However, the documents 
gave conflicting conclusions regarding the treatment, including 
corticosteroids and alternative immunosuppressants (6, 7). We 
recently experienced a patient with isolated spinal cord sarcoid-
osis, which was confirmed by tissue biopsy and well responsive 
to high-dose corticosteroid and immunosuppressant. 
 
CASE DESCRIPTION
A 54-yr-old woman, with no significant past medical history, 
presented with progressive 4-extremities weakness and sensory 
changes, followed by urinary difficulty since 1 month ago and 
was admitted to our hospital in October 2007. Physical exami-
nation revealed increased deep tendon reflex, positive Babinski 
sign and decreased motor power with medical research council 
(MRC) grade 2 strength in the right side and MRC grade 4 strength 
in the left side. Pinprick and temperature sensation was decreased 
from C4, dominantly in the left side. Vibration and propriocep-
tion was decreased, dominantly in the right side. Hoffman’s and 
Tromner’s sign were increased in both hands. Initial magnetic 
resonance imaging (MRI) revealed increased T2 signal from C4 
to C6 level, edematous expansion of the cord and intense nod-
ular enhancement (Fig. 1A). Based on the MRI, spinal cord tu-
mor, demyelinating disease involving multiple sclerosis, neuro-
myelitis optica and acute tranverse myelitis were suspected. 
Serological studies for systemic autoimmunity, including rheu-
matoid factor and antinuclear, anti-dsDNA, anti-SSA/SSB, and 
antiphospholipid antibodies, showed no abnormality. The cere-Ahn S-W, et al.  •  Spinal Cord Sarcoidosis
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brospinal fluid (CSF) analysis including biochemistry, IgG index 
and oligoclonal band was normal. One month later, the follow-
up spinal MRI showed the more extended lesion relative to pre-
vious MRI, and which highly suggested the spinal cord tumor 
such as intramedullary astrocytoma (Fig. 1B). Based on the sus-
picion of intramedullary astrocytoma, the laminectomy and tis-
sue biopsy of 2 µL, which showed yellowish color, were performed 
at the central portion of dorsal column in affected cervical cord 
lesion. Postoperatively, patient’s neurologic deficits were not 
aggravated and, unexpectedly, the histology of biopsy revealed 
non-caseating granuloma without malignant cell (Fig. 2A). AFB 
and PAS staining of tissue were negative (Fig. 2B, C). The diag-
nosis was changed from intramedullary astrocytoma to neuro-
sarcoidosis. Angiotesin converting enzyme (ACE) was mildly 
elevated to 56 (U/L; normal, < 52 U/L). On the systemic evalua-
tions, there was no disease activity on other organs with using 
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Fig. 1. T2-weighted and gadolinium enhanced T1-weighted cervical MRI in the patient. (A) Initial cervical spine MRI (magnetic resonance image) revealed increased T2 signal 
from C4 to C6 level, edematous expansion of the cord and intense nodular enhancement. Based on the MRI, spinal cord tumor, demyelinating disease and acute tranverse 
myelitis were suspected. (B) One month later, the follow-up spinal MRI showed the extended lesion relative to previous MRI, and which highly suggested the spinal cord tumor 
such as intramedullay astrocytoma. (C) Demonstrates cervical spine MRI after laminectomy and tissue biopsy. (D) The patient was treated with high-dose corticosteroid and 
immunosuppressant for over 2 yr and spinal cord lesion was much resolved in MRI. 
Fig. 2. Histopathology of the biopsied cervical cord lesion. 
(A) The specimen biopsied from the lesion contained multi-
nucleated giant cells (red arrows), lymphocytes (black arrow) 
and aggregated histiocytes (white arrow) within granuloma-
tous inflammation, consistent with non-caseating granuloma 
seen in sarcoidosis (H&E staining × 200). (B) The AFB stain-
ing of the specimen did not show the mycobacterium tuber-
culosis. PAS staining did not reveal the fungus.  A
B
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brain MRI, chest and abdominal computed tomography and 
nerve conduction study (NCS). The patient was treated with 
high-dose corticosteroid (60 mg/day) followed by methotrexate 
(10 mg/week) for over 2 yr. Two years later, cervical spinal cord 
lesion was much improved in the spinal MRI (Fig. 1D), however 
clinical symptoms of weakness and sensory change were not 
definitely improved. Recently, the patient had to stop corticoste-
roid medication because of the cellulitis in the left leg. Instead, 
we tried thalidomide 100 mg daily for 1 month with the goal of 
titrating up to 400 mg per day, which had been reported to be 
effective in the refractory neurosarcoidosis (11). However the 
patient refused high-dose thalidomide due to severe fatigue and 
high cost, and just treated with low-dose thalidomide (100 mg/
day) and treatment did not show distinct effect in our patient.
 
DISCUSSION
The spinal cord sarcoidosis is very rare and the diagnosis of this 
entity is difficult, as there are no pathognomic diagnostic study 
for neurosarcoidosis (3, 12, 13). In general, this disease has been 
diagnosed clinically using MRI, lumbar puncture and attendant 
laboratory tests, and the diagnosis is possible when systemic 
sarcoidosis is detected in other organs involving lung, kidney, 
eye and skin. Spinal cord sarcoidosis may present as an idiopath-
ic inflammatory demyelinating disease both clinically and radio-
logically (5). Only a positive biopsy of suspicious lesions in the 
central nervous system is considered to be definitive confirma-
tion of the diagnosis of isolated neurosarcoidosis. Zajicek and 
colleagues established a diagnostic classification system for neu-
rosarcoidosis that distinguished ‘definite’ , ‘probable’ and ‘possi-
ble’ neurosarcoidosis based on tissue evidence of non-caseating 
granuloma and supportive evidence of sarcoid pathology in lab-
oratory and imaging studies (13). However, biopsy should be 
cautiously considered if possible because of the risk involved in 
approaching the spinal cord. Our patient was initially suspected 
to have intramedullary astrocytoma or multiple sclerosis based 
on neurologic symptoms and MRI results. Of course, the possi-
bility of multiple sclerosis was not high because the clinical symp-
toms and cervical lesion were gradually progressive for months. 
The spinal cord biopsy was challenging procedure, nevertheless 
the cord biopsy and laminectomy were performed for diagnos-
tic confirmation in the consent of patient, and the histology of 
which was unexpectedly consistent with sarcoidosis. The histol-
ogy revealed multinucleated giant cells, lymphocytes and ag-
gregated histiocytes within granulomatous inflammation, con-
sistent with non-caseating granuloma seen in sarcoidosis. This 
is a rare case confirmed by direct tissue biopsy in the spinal cord. 
A few cases with neurosarcoidosis have been reported, however 
most cases suggested only clinical manifestation without his-
tology, or demonstrated indirect biopsy in the brain, meninges 
and lymph node (6-10).
  With an initial treatment, we tried high dose corticosteroid 
and immunosuppressant. Systemic corticosteroids and immu-
nosuppressive therapy are the treatment of choice for neurosar-
coidosis, however which shows partial response especially in 
the spinal cord neurosarcoidosis (4, 6-10). Unfortunately, 25% 
of neurosarcoidosis still have a refractory course with steroid 
treatment and, and 20%-40% of those refractory patients will 
not respond to current conventional immunosuppressant (3). 
In our case, the clinical symptoms were initially severe and rap-
idly progressive, and therefore the combined therapy of high-
dose corticosteroid and immunosuppressant was necessary. 
Combination with immunosuppressant was useful to improve 
symptom control and reduce corticosteroid-related side effects 
in some cases. Fortunately, our patient responded well to high-
dose corticosteroid and immunosuppressant. Therefore, mak-
ing a diagnosis of neurosarcoidosis was therapeutically essen-
tial, since corticosteroid and immunosuppressant treatment 
must be started and continued for years in order to prevent pro-
gression and permanent disability. A few reports have docu-
mented that the high-dose thalidomide (400 mg/day) was ef-
fective in the refractory neurosarcoidosis (11), and so we tried 
low-dose thalidomide (100 mg/day) for one month in our pa-
tient. However there was no clear evidence that thalidomide 
was effective in our case of neurosarcoidosis, although there 
was limitation on the dosage and duration of treatment com-
pared with other cases. 
  Our case indicates that diagnosis of spinal cord sarcoidosis is 
not easy and may require histological examination, and high-
dose corticosteroid and immunosuppressant will be a good 
choice in the treatment of spinal cord sarcoidosis, and the tha-
lidomide has to be debated in the treatment of spinal cord sar-
coidosis.  
  This is the first Korean case, to our knowledge, which shows 
an isolated spinal cord sarcoidosis confirmed by direct tissue 
biopsy and good response to corticosteroid and immunosup-
pressant. 
REFERENCES
1. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361: 
1111-8.
2. Stern BJ. Neurological complications of sarcoidosis. Curr Opin Neurol 
2004; 17: 311-6.
3. Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical 
dilemma. Lancet Neurol 2004; 3: 397-407.
4. Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neu-
rol Neurosurg Psychiatry 2009; 80: 297-304.
5. Shah R, Roberson GH, Curé JK. Correlation of MR imaging findings and 
clinical manifestations in neurosarcoidosis. AJNR Am J Neuroradiol 2009; 
30: 953-61.
6. Varron L, Broussolle C, Candessanche JP, Marignier R, Rousset H, Ninet 
J, Sève P. Spinal cord sarcoidosis: report of seven cases. Eur J Neurol 2009; Ahn S-W, et al.  •  Spinal Cord Sarcoidosis
http://jkms.org   157 DOI: 10.3346/jkms.2011.26.1.154
16: 289-96.
7. Scott TF, Yandora K, Valeri A, Chieffe C, Schramke C. Aggressive thera-
py for neurosarcoidosis: long-term follow-up of 48 treated patients. Arch 
Neurol 2007; 64: 691-6.
8. Caneparo D, Lucetti C, Nuti A, Cipriani G, Tessa C, Fazzi P, Bonuccelli U. 
A case of sarcoidosis presenting as a non-specific intramedullary lesion. 
Eur J Neurol 2007; 14: 346-9.
9. Bhagavati S, Choi J. Intramedullary cervical spinal cord sarcoidosis. Spi-
nal Cord 2009; 47: 179-81.
10. Maroun FB, O’Dea FJ, Mathieson G, Fox G, Murray G, Jacob JC, Reddy R, 
Avery R. Sarcoidosis presenting as an intramedullary spinal cord lesion. 
Can J Neurol Sci 2001; 28: 163-6.
11. Hammond ER, Kaplin AI, Kerr DA. Thalidomide for acute treatment of 
neurosarcoidosis. Spinal Cord 2007; 45: 802-3.
12. Viñas FC, Rengachary S, Kupsky WJ. Spinal cord sarcoidosis: a diagnos-
tic dilemma. Neurol Res 2001; 23: 347-52.
13. Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, Scad-
ding JW, Thompson EJ, Chamoun V, Miller DH, McDonald WI, Mitchell 
D. Central nervous system sarcoidosis–diagnosis and management. QJM 
1999; 92: 103-17.